147.28MMarket Cap-749P/E (TTM)
1.825High1.790Low8.13KVolume1.790Open1.810Pre Close14.62KTurnover0.02%Turnover RatioLossP/E (Static)80.70MShares3.38052wk High0.62P/B97.28MFloat Cap1.16052wk Low--Dividend TTM53.30MShs Float85.400Historical High--Div YieldTTM1.93%Amplitude1.160Historical Low1.798Avg Price1Lot Size
I-Mab Stock Forum
Select biotech/pharma names showing strength following ESMO:
$Clovis Oncology(CLVS.US)$ +11.3%, $Cardiff Oncology(CRDF.US)$ +9%, $Immatics(IMTX.US)$ +8.3%, $IDEAYA Biosciences(IDYA.US)$ +8%, $Lyra Therapeutics(LYRA.US)$ +5.7%, $POINT Biopharma(PNT.US)$ +5.7%, $Edgewise Therapeutics(EWTX.US)$ +4.7%, $Concert Pharmaceuticals(CNCE.US)$ +3.6%, $Deciphera Pharmaceuticals(DCPH.US)$ +3.2%, $Veracyte(VCYT.US)$ +2.6%, $SpringWorks Therapeutics(SWTX.US)$ +2.3%,...
$I-Mab(IMAB.US)$
this pharmaceutical company has tons of potential big money makers in the pipeline. if just one of these Cancer drugs gets approved then it will be a lot of money to be made for this very cheap ticker. they're also anticipating being listed in mainland China and in Hong Kong. this could be a bullish catalyst in the future even without any of the drugs being approv...
• $GTY Technology(GTYH.US)$ +118.1% (entered into a definitive agreement to be acquired by GI Partners )
• $Finch Therapeutics(FNCH.US)$ +68.33% (announces removal of FDA clinical hold on CP101 IND)
• $Zymeworks(ZYME.US)$ +42.34% (confirms receipt of non-binding proposal from All Blue Falcons for $10.50 per share in cash)
• $Hub Group(HUBG.US)$ +16.3% (earnings reports)
• $Lantheus(LNTH.US)$ +14.2% (earnings reports)
• $Mohawk Industries(MHK.US)$ +13.7% (e...
• $AlloVir(ALVR.US)$ +23.11% (announced that the U.S. Food and Drug Administration has granted Regenerative Medicine Advanced Therapy designation to its lead investigational multi-virus-specific T cell therapy posoleucel)
• $I-Mab(IMAB.US)$ +13% (report that the company is considering sale)
• $ASML Holding(ASML.US)$ +5.2% (earnings report)
• $Humanigen(HGEN.US)$ +4.4% (Announces Peer-Reviewed Publication Demonstrating the P...
No comment yet